about
Human parathyroid hormone for preventing and treating glucocorticoid-induced osteoporosisThe pharmacological management of osteoporosisEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal womenManagement of osteoporosisA review of the methods used to define glucocorticoid exposure and risk attribution when investigating the risk of fracture in a rheumatoid arthritis populationNew perspectives in echographic diagnosis of osteoporosis on hip and spineGlucocorticoid-induced osteoporosisManagement of endocrine disease: Secondary osteoporosis: pathophysiology and managementDeterminants of Muscle and Bone AgingDisorders of bone remodelingPublic health impact of adverse bone effects of oral corticosteroidsData Resource Profile: Clinical Practice Research Datalink (CPRD)Imminent fracture risk.Management of glucocorticoid-induced osteoporosis: clinical data in relation to disease demographics, bone mineral density and fracture risk.Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.Effects of bisphosphonate administration on the bone mass in immune thrombocytopenic purpura patients under treatment with steroids.UK clinical guideline for the prevention and treatment of osteoporosisMale osteoporosis and androgenic therapy: from testosterone to SARMs.Osteogenic differentiation of human amniotic fluid-derived stem cells induced by bone morphogenetic protein-7 and enhanced by nanofibrous scaffolds.Prevention and treatment of corticosteroid-induced osteoporosisSkeletal recovery after weaning does not require PTHrP.Increased risk of fragility fractures among HIV infected compared to uninfected male veterans.What old means to bone.Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies.Influence of glucocorticoids on the osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells.Gender differences for initiating teriparatide therapy: baseline data from the Direct Assessment of Nonvertebral Fracture in the Community Experience (DANCE) study.A systematic review and meta-analysis of glucocorticoid-induced osteoporosis in children.Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosisIn vivo NMR microscopy allows short-term serial assessment of multiple skeletal implications of corticosteroid exposureReduced fracture risk with early corticosteroid withdrawal after kidney transplant.Bone health should be an important concern in the care of patients affected by 21 hydroxylase deficiency.The effect of metyrosine/prednisolone combination to oophorectomy-induced osteoporosis.Osteoporosis in systemic lupus erythematosus: prevention and treatment.Role of teriparatide in treatment of glucocorticoid-induced osteoporosisRelationship between use of antidepressants and risk of fractures: a meta-analysis.2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.An N-ethyl-N-nitrosourea induced corticotropin-releasing hormone promoter mutation provides a mouse model for endogenous glucocorticoid excessMedication-induced osteoporosis: screening and treatment strategiesAbnormalities in cortical bone, trabecular plates, and stiffness in postmenopausal women treated with glucocorticoids.Outcomes and secondary prevention strategies for male hip fractures.
P2860
Q24194063-1467FC48-04F6-4249-8073-5C8EE99AE19EQ24605290-3374E3FA-2E8C-4CDD-AF00-A4A4AEC625D8Q24612411-4E3FB4E9-5D68-4E5A-80AB-440B9F1C54ACQ24795473-E7B2C0F0-80FF-4AFF-9790-F24F3213E056Q26748556-970C27D8-2F79-42C4-B03C-613A2BDC263BQ26775752-81C8171D-FF40-48AD-A3E5-2D855A122148Q26778272-9125160C-75F5-41B7-8ABB-5670B4866878Q26998249-16ED4622-901B-4A60-8842-C78EF3AE8D42Q26998480-71D5C609-6792-42CF-B002-12345969C945Q28295303-D533A2BF-631F-45DC-897E-0A775DC30DB9Q28367572-E35A3246-1A11-4E6F-BB35-8E25BED3F441Q28645951-B50721A0-1169-4339-83FB-3BB1C02F474AQ30235569-4C85C5FE-EE8F-41E3-AB91-F5CA6FB28E57Q30946308-5DC6B75B-5935-4DEC-9123-22A23246C47EQ31000488-2F55B590-83CC-4F89-AE87-84900F11F349Q33387310-6726C482-4C60-4CD8-BE61-EFA93E6B8EE5Q33581078-5590C1CC-067C-4EC1-AA02-A015D90F1270Q33610301-56A1EE71-646B-4BD6-AE18-7A9C258B26AEQ33621125-AD17A7A1-5031-46AA-9F20-F23963625FE5Q33628208-02C9404F-3685-4554-B771-99FFE435EF21Q33817186-061BA7BA-8C9A-47C3-8187-93FADCB70244Q33832012-C047DE1C-2C40-4BA5-85A3-5C8D6F6735D8Q33892053-C7F03CB9-77E1-4284-BD91-96D51FA53746Q33893627-C9C422CE-0016-4C9C-BD9D-0730734C5457Q33942172-30E24A0C-69BA-4405-8C5D-2F23A9F7EC19Q33965079-FBBBB95C-4360-4614-86BD-C0F8A8E1D287Q33993628-A26D7B20-000C-4DE4-8217-D461132DD273Q34042003-7A7FA192-4A12-46BF-9BAD-DB62AF543ACCQ34049051-C6108006-9B61-4F4F-9455-C64E779542CDQ34069674-E1A2A9F0-FF72-4B61-9154-3F63095F083FQ34169844-F59F3DD9-AE11-42E4-BF7D-766BE19AA641Q34196596-CD67AFF4-7B43-4755-848D-4D2FE5F42EB3Q34227091-86FFDB21-E085-4498-A93E-55B06A6AF340Q34235921-275C87AA-732E-4F96-AE3A-BD8E954A695DQ34277620-C397B7BC-8E15-4864-8F29-169F539B97A5Q34300668-281E6101-E246-4D62-A459-3C219B82E012Q34316496-FFAA3ACC-86A7-4921-B3F1-D257A09552D9Q34389358-AC7C4982-F835-43AB-AC79-B549C0ACC54FQ34468133-69967303-CA75-49A9-A414-794356194947Q34509405-52823589-793A-4C1B-AB53-4B9B4D719132
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Use of oral corticosteroids and risk of fractures.
@ast
Use of oral corticosteroids and risk of fractures.
@en
type
label
Use of oral corticosteroids and risk of fractures.
@ast
Use of oral corticosteroids and risk of fractures.
@en
prefLabel
Use of oral corticosteroids and risk of fractures.
@ast
Use of oral corticosteroids and risk of fractures.
@en
P2093
P1476
Use of oral corticosteroids and risk of fractures
@en
P2093
P304
P356
10.1359/JBMR.2000.15.6.993
P577
2000-06-01T00:00:00Z